Please provide your email address to receive an email when new articles are posted on . MONTREAL — Spiriva Respimat, as an add-on to inhaled corticosteroids or long-acting beta2 agonists, reduced the ...
Please provide your email address to receive an email when new articles are posted on . Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for ...
RIDGEFIELD, Conn., May 23, 2017 /PRNewswire/ -- Boehringer Ingelheim today announced new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient ...
RIDGEFIELD, Conn., Feb. 3, 2020 /PRNewswire/ -- Boehringer Ingelheim today presented results from a new retrospective analysis of real-world data that showed patients prescribed Spiriva® Respimat® ...
Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...
Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market Spiriva® Respimat® in the European Union for people with chronic obstructive ...
SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside the US, the UK & Canada only Boehringer Ingelheim today announced that the indication for Spiriva ® (tiotropium) Respimat ®* in asthma has been ...
The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...
BARCELONA, Spain — The risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist ...
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results